The Development of Biomarkers in Lung Cancer

Clinical Pearls

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, comments on the development of biomarkers for lung cancer.

• Every tumor has a different driver. The point has been reached where combinations seem to be future.
• Developing appropriate drug combinations is challenging, partly because of toxicity.
• There remains a need to further understand tumor biology to target it more specifically.